什么时候使用静脉注射免疫球蛋白适用于免疫性血小板缩?
Sydney Dubois1,2, Richard Layese3,4, Nicolas Limal1
1Internal Medicine Department, Centre National de Référence des Cytopénies Auto-Immunes de l'Adulte, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil (UPEC), Créteil, France.
British journal of haematology
|October 10, 2024
概括
法国指导方针限制静脉注射免疫球蛋白 (IVIg) 用于免疫血小板缺血症 (ITP). 一项研究发现,针对ITP的IVIg处方中有84.4%符合指导方针,年轻患者不遵守指导方针的频率更高.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 静脉注射免疫球蛋白 (IVIg) 是重症免疫血小板缺血症 (ITP) 的首要治疗方法.
- 法国指南限制IVIg的使用,原因是成本,疗效持续时间和供应问题.
- 指导方针优先考虑IVIg对皮质类固醇禁忌,高出血分数 (Khelaf分数>8) 或特定临床背景的患者.
研究的目的:
- 为了评估IVIg对ITP的实际处方实践.
- 评估是否遵守目前法国关于在ITP患者中使用IVIg的指南.
- 确定与不符合IVIg处方相关的因素.
主要方法:
- 这是一项对114名住院ITP患者的单心回顾性研究.
- 分析了2016年至2020年间进行的208次IVIg治疗.
- 基于法国指导方针和患者临床数据的IVIg处方有效性的评估,包括Khellaf评分.
主要成果:
- 在84.4%的病例中,IVIg处方符合法国指南.
- 在37%的病例中,处方被Khelaf分数> 8验证.
- 违规原因包括皮质类固醇耐药性 (33.7%),侵入性手术准备 (8.5%),怀孕 (6.6%) 和皮质类固醇禁用 (3.3%). 在年轻患者中,违规率更高 (p=0.027).
结论:
- 现实世界IVIg对ITP的处方在很大程度上符合法国的指导方针.
- 较年轻的患者和服用抗凝血药物的患者可以在严格的指导参数之外接受IVIg.
- 进一步的研究可能会完善最佳IVIg在ITP管理中的使用指南.
相关概念视频
01:29Venous Thrombosis III: Interprofessional Care
3
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
3
02:45Blood Transfusion and Agglutination
10.7K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
10.7K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
633
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
633
01:27Tumor Immunotherapy
488
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
488